Verona Pharma (VRP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

Trade now with BarclaysStockbrokers Trade now with Barclays Sponsored by Barclays Stockbrokers

123.50p
   
  • Change Today:
      1.50p
  • 52 Week High: 206.25
  • 52 Week Low: 111.00
  • Currency: UK Pounds
  • Shares Issued: 104.88m
  • Volume: 17,934
  • Market Cap: 129.53m
  • RiskGrade: 138

Verona Pharma Overview

Verona Pharma is developing first in class drugs to treat respiratory disease such as COPD asthma and chronic severe cough

1 Day Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 3.8  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Verona Pharma Fundamentals

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-12 n/a (2.57) (39.35)p n/a n/a n/a n/a 0.0%
31-Dec-13 n/a (2.81) (35.51)p n/a n/a n/a n/a 0.0%
31-Dec-14 n/a (3.76) (16.00)p n/a n/a n/a n/a 0.0%
31-Dec-15 n/a (9.00) (1,855.00)p n/a n/a n/a n/a 0.0%
31-Dec-16 n/a (5.97) (749.00)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Verona Pharma Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 n/a (15.18) (46.01)p n/a n/a n/a n/a 0.0%
31-Dec-18 n/a (27.59) (84.33)p n/a n/a n/a n/a 0.0%

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.

Verona Pharma Company Announcements

Verona Pharma plc Interim Results for the Six Mo... 08-Aug-2017 07:00 GlobeNewswire EU
Verona Pharma to Announce Interim Results for Si... 02-Aug-2017 16:00 GlobeNewswire EU
Verona Pharma to Present at 2017 Wedbush PacGrow... 01-Aug-2017 12:05 GlobeNewswire EU

Latest Verona Pharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Verona Pharma Market Data

Currency UK Pounds
Share Price 123.50p
Change Today 1.50p
% Change 1.23 %
52 Week High 206.25
52 Week Low 111.00
Volume 17,934
Shares Issued 104.88m
Market Cap 129.53m
RiskGrade 138

Verona Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
49.94% below the market average49.94% below the market average49.94% below the market average49.94% below the market average49.94% below the market average
20.69% below the sector average20.69% below the sector average20.69% below the sector average20.69% below the sector average20.69% below the sector average
Price Trend
67.72% below the market average67.72% below the market average67.72% below the market average67.72% below the market average67.72% below the market average
29.03% below the sector average29.03% below the sector average29.03% below the sector average29.03% below the sector average29.03% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 4
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Verona Pharma Dividends

No dividends found

Trades for 18-Aug-2017

Time Volume / Share Price
12:05 2,500 @ 123.00p
12:05 4,009 @ 124.40p
11:09 10,000 @ 123.00p
11:05 1,125 @ 121.00p
09:19 300 @ 123.00p

Verona Pharma Key Personnel

CEO Sven Jan-Anders Karlsson
CFO Piers Morgan

Top of Page